NCT03919929View on ClinicalTrials.gov

Treating PCOS With Semaglutide vs Active Lifestyle Intervention

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 3, 2019

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
PCOSAdolescent ObesityNAFLD
Interventions
DRUG

Semaglutide 3mg and 7mg [Rybelsus]

Once daily oral tablet of semaglutide for 4 months

OTHER

Weight loss diet

Prescribed weight loss diet to match weight loss in Drug arm

Trial Locations (1)

80045

University of Colorado Anshutz Medical Campus/Children's Hospital Colorado, Aurora

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Colorado, Denver

OTHER